Skip to main content

Advertisement

Springer Nature Link
Log in

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Introduction

Ulcerated melanomas may have a unique biology and microenvironment. We test whether markers of immune infiltration correlate with clinical outcome in ulcerated compared to non-ulcerated primary melanoma tumors.

Methods

Sixty-two stage II–III cutaneous melanomas, 32 ulcerated and 30 non-ulcerated, were analyzed for tumor-infiltrating lymphocytes (TILs). Immunohistochemistry (IHC) was performed for CD2, a marker previously shown to correlate with overall survival (OS) and recurrence-free survival (RFS) in this patient population. IHC using antibody, VE1, to BRAF V600E was also performed on a subset of 41 tumors to assess the relationship of BRAF mutation to immune markers.

Results

We found, using Cox regression models, that the presence of TILs was associated with improved OS (p = 0.034) and RFS (p = 0.002) in ulcerated melanoma tumors, but not in non-ulcerated melanoma (p = 0.632, 0.416). CD2 expression also was correlated with improved OS (p = 0.021) and RFS (p = 0.001) in ulcerated melanoma, but no relationship was seen in non-ulcerated melanoma (p = 0.427, 0.682). In this small population, BRAF status did not correlate with TILs or CD2+ count.

Conclusion

Our data show that immune markers including TILs and CD2 count correlate more closely with survival in ulcerated melanomas than that in non-ulcerated melanomas. We propose that immune biomarkers may be particularly relevant to ulcerated, as compared to non-ulcerated, melanomas and that this merits study in larger populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

AJCC:

American Joint Committee on Cancer

Ang-2:

Angiopoietin 2

EORTC:

European Organisation for Research and Treatment of Cancer

FFPE:

Formalin fixed paraffin embedded

GMC:

Geisinger Medical Center

HPF:

High-powered field

IHC:

Immunohistochemistry

IRB:

Institutional review board

ISMMS:

Icahn School of Medicine at Mount Sinai

LFA-3:

Lymphocyte function-associated antigen-3

OS:

Overall survival

RFS:

Recurrence-free survival

TILs:

Tumor-infiltrating lymphocytes

TNBC:

Triple-negative breast cancer

References

  1. Allen AC, Spitz S (1953) Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 6:1–45

    Article  CAS  PubMed  Google Scholar 

  2. Eggermont AM, Spatz A, Lazar V, Robert C (2012) Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 24:137–140. doi:10.1097/CCO.0b013e32834fcb0d

    Article  PubMed  Google Scholar 

  3. McMasters KM, Edwards MJ, Ross MI et al (2010) Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg. 252:460–465; discussion 465–466. doi: 10.1097/SLA.0b013e3181f20bb1

  4. Suciu S, Ives N, Eggermont AM, Kirkwood JM, Lorigan P, Markovic S, Garbe C, Wheatley K (2014) Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): AN individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). J Clin Oncol 32 (suppl; abstr 9067)

  5. Eggermont AM, Suciu S, Testori A et al (2012) Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810–3818. doi:10.1200/JCO.2011.41.3799

    Article  CAS  PubMed  Google Scholar 

  6. Spatz A, Batist G, Eggermont AM (2010) The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 22:163–168. doi:10.1097/CCO.0b013e328337fe8f

    Article  CAS  PubMed  Google Scholar 

  7. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45:3012–3017

    Article  CAS  PubMed  Google Scholar 

  8. Aviles-Izquierdo JA, Lazaro-Ochaita P (2012) Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin Transl Oncol 14:237–240. doi:10.1007/s12094-012-0790-6

    Article  PubMed  Google Scholar 

  9. Eigentler TK, Buettner PG, Leiter U, Garbe C, Central Malignant Melanoma Registry of the German Dermatological S (2004) Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol. 22:4376–4383. doi:10.1200/JCO.2004.03.075

    Article  PubMed  Google Scholar 

  10. Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634

    CAS  PubMed  Google Scholar 

  11. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd (2002) Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 20:1826–1831

    Article  PubMed  Google Scholar 

  12. Jewell R, Elliott F, Laye J et al (2015) The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res 28:94–104. doi:10.1111/pcmr.12315

    Article  CAS  PubMed  Google Scholar 

  13. Suciu S, Ives N, Eggermont AM, Kirkwood JM, Lorigan P, Markovic S, Garbe C, Wheatley K (2014) Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). J Clin Oncol 32 (suppl; abstr9067)

  14. Grande Sarpa H, Reinke K, Shaikh L, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2006) Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol 30:1396–1400. doi:10.1097/01.pas.0000213262.61855.7d

    Article  PubMed  Google Scholar 

  15. Qian M, Ma MW, Fleming NH, Lackaye DJ, Hernando E, Osman I, Shao Y (2013) Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. Melanoma Res 23:461–467. doi:10.1097/cmr.0000000000000015

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Adams S, Gray RJ, Demaria S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959–2966. doi:10.1200/JCO.2013.55.0491

    Article  PubMed  Google Scholar 

  17. Loi S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860–867. doi:10.1200/JCO.2011.41.0902

    Article  CAS  PubMed  Google Scholar 

  18. Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128. doi:10.1126/science.aaa1348

    Article  CAS  PubMed  Google Scholar 

  19. Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199. doi:10.1056/NEJMoa1406498

    Article  PubMed Central  PubMed  Google Scholar 

  20. Goldsmith LA, Fitzpatrick TB (2012) Fitzpatrick’s dermatology in general medicine. McGraw-Hill Medical, New York. Access Medicine. Web. September 28, 2014

  21. Gallois A, Bhardwaj N (2013) Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol 4:436. doi:10.3389/fimmu.2013.00436

    Article  PubMed Central  PubMed  Google Scholar 

  22. Kashani-Sabet M (2010) Tumor progression by immune evasion in melanoma. Cancer 116:1623–1625. doi:10.1002/cncr.24909

    Article  PubMed  Google Scholar 

  23. Mandala M, Imberti GL, Piazzalunga D et al (2009) Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer 45:2537–2545. doi:10.1016/j.ejca.2009.05.034

    Article  CAS  PubMed  Google Scholar 

  24. Burton AL, Roach BA, Mays MP et al (2011) Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 77:188–192

    PubMed  Google Scholar 

  25. Bogunovic D, O’Neill DW, Belitskaya-Levy I et al (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 106:20429–20434. doi:10.1073/pnas.0905139106

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Harcharik S, Bernardo S, Moskalenko M et al (2014) Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. J Am Acad Dermatol 70:1036–1044. doi:10.1016/j.jaad.2014.01.914

    Article  PubMed  Google Scholar 

  27. Green JM, Karpitskiy V, Kimzey SL, Shaw AS (2000) Coordinate regulation of T cell activation by CD2 and CD28. J Immunol. 164:3591–3595

    Article  CAS  PubMed  Google Scholar 

  28. Tibaldi EV, Salgia R, Reinherz EL (2002) CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance. Proc Natl Acad Sci USA 99:7582–7587. doi:10.1073/pnas.112212699

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Crawford K, Stark A, Kitchens B et al (2003) CD2 engagement induces dendritic cell activation: implications for immune surveillance and T-cell activation. Blood 102:1745–1752. doi:10.1182/blood-2002-07-2206

    Article  CAS  PubMed  Google Scholar 

  30. Mihm MC Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43–47

    PubMed  Google Scholar 

  31. Capper D, Preusser M, Habel A et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19. doi:10.1007/s00401-011-0841-z

    Article  CAS  PubMed  Google Scholar 

  32. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30:2678–2683. doi:10.1200/JCO.2011.37.8539

    Article  PubMed  Google Scholar 

  33. Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G (2013) Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol 169:320–328. doi:10.1111/bjd.12351

    Article  CAS  PubMed  Google Scholar 

  34. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63:3883–3885

    CAS  PubMed  Google Scholar 

  35. van Rijn P, Rijmen F (2015) On the explaining-away phenomenon in multivariate latent variable models. Br J Math Stat Psychol 68:1–22. doi:10.1111/bmsp.12046

    Article  PubMed  Google Scholar 

  36. De Panfilis G, Campanini N, Santini M et al (2008) Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol. 128:676–684. doi:10.1038/sj.jid.5701046

    PubMed  Google Scholar 

  37. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206. doi:10.1200/JCO.2009.23.4799

    Article  PubMed Central  PubMed  Google Scholar 

  38. Fried L, Arbiser JL (2008) The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 21:117–122. doi:10.1111/j.1755-148X.2008.00451.x

    Article  CAS  PubMed  Google Scholar 

  39. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081. doi:10.1093/carcin/bgp127

    Article  CAS  PubMed  Google Scholar 

  40. Eggermont AM, Suciu S, Testori A et al (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218–225. doi:10.1016/j.ejca.2011.09.028

    Article  CAS  PubMed  Google Scholar 

  41. Baurain J, Stas M, Hammouch F et al (2009) Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor-specific antigenic peptides. ASCO Meet Abstr 27:3022

    Google Scholar 

  42. Han D, Zager JS, Shyr Y et al (2013) Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31:4387–4393. doi:10.1200/JCO.2013.50.1114

    Article  PubMed  Google Scholar 

  43. Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39:11–26. doi:10.1016/j.immuni.2013.07.008

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The study was funded by Dermatology Foundation (Career Development Award), American Association for Cancer Research (Landon Cancer Immunology Innovator Award), Herbert Irving Comprehensive Cancer Center at Columbia University, and Tisch Cancer Center at the Icahn School of Medicine at Mount Sinai.

Conflict of interest

The authors have no conflict of interest to declare.

Author information

Author notes

    Authors and Affiliations

    1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

      Ellen H. de Moll, Sara H. Perkins, Shira Wieder, Sebastian G. Bernardo, Jerry Chipuk, Miriam B. Birge, Robert G. Phelps & Yvonne M. Saenger

    2. Department of Medicine, Columbia University College of Physicians and Surgeons, 177 Fort Washington Avenue, New York, NY, 10032, USA

      Yichun Fu, Yingzhi Qian & Yvonne M. Saenger

    3. Hematology Oncology Division, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

      Sacha Gnjatic, Romain Remark, Marina Moskalenko, Miriam B. Birge, Robert G. Phelps & Yvonne M. Saenger

    4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

      Jonathan Yao & Jerry Chipuk

    5. Geisinger Medical Center, Danville, PA, USA

      Tammie Ferringer

    6. Department of Genetics and Genomic Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA

      Rui Chang

    7. Department of Pathology, Columbia University College of Physicians and Surgeons, New York, NY, USA

      Basil A. Horst

    Authors
    1. Ellen H. de Moll
      View author publications

      You can also search for this author inPubMed Google Scholar

    2. Yichun Fu
      View author publications

      You can also search for this author inPubMed Google Scholar

    3. Yingzhi Qian
      View author publications

      You can also search for this author inPubMed Google Scholar

    4. Sara H. Perkins
      View author publications

      You can also search for this author inPubMed Google Scholar

    5. Shira Wieder
      View author publications

      You can also search for this author inPubMed Google Scholar

    6. Sacha Gnjatic
      View author publications

      You can also search for this author inPubMed Google Scholar

    7. Romain Remark
      View author publications

      You can also search for this author inPubMed Google Scholar

    8. Sebastian G. Bernardo
      View author publications

      You can also search for this author inPubMed Google Scholar

    9. Marina Moskalenko
      View author publications

      You can also search for this author inPubMed Google Scholar

    10. Jonathan Yao
      View author publications

      You can also search for this author inPubMed Google Scholar

    11. Tammie Ferringer
      View author publications

      You can also search for this author inPubMed Google Scholar

    12. Rui Chang
      View author publications

      You can also search for this author inPubMed Google Scholar

    13. Jerry Chipuk
      View author publications

      You can also search for this author inPubMed Google Scholar

    14. Basil A. Horst
      View author publications

      You can also search for this author inPubMed Google Scholar

    15. Miriam B. Birge
      View author publications

      You can also search for this author inPubMed Google Scholar

    16. Robert G. Phelps
      View author publications

      You can also search for this author inPubMed Google Scholar

    17. Yvonne M. Saenger
      View author publications

      You can also search for this author inPubMed Google Scholar

    Corresponding author

    Correspondence to Yvonne M. Saenger.

    Additional information

    Ellen H. de Moll and Yichun Fu have contributed equally to this article and should be considered co-first authors.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (PDF 200,267 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    de Moll, E.H., Fu, Y., Qian, Y. et al. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother 64, 1193–1203 (2015). https://doi.org/10.1007/s00262-015-1726-0

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00262-015-1726-0

    Keywords